Price T Rowe Associates Inc. MD Has $1.69 Million Holdings in Immuneering Co. (NASDAQ:IMRX)

Price T Rowe Associates Inc. MD reduced its position in shares of Immuneering Co. (NASDAQ:IMRX) by 5.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 767,124 shares of the company’s stock after selling 43,003 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Immuneering were worth $1,688,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new stake in shares of Immuneering in the 4th quarter valued at about $47,000. XTX Topco Ltd lifted its position in shares of Immuneering by 177.2% in the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock valued at $72,000 after buying an additional 20,871 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of Immuneering by 33.7% during the 4th quarter. HighTower Advisors LLC now owns 71,360 shares of the company’s stock worth $157,000 after acquiring an additional 18,000 shares during the period. Finally, Rockefeller Capital Management L.P. acquired a new position in shares of Immuneering during the 4th quarter worth approximately $390,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Chardan Capital reaffirmed a “buy” rating and set a $13.00 price objective on shares of Immuneering in a research report on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price target on shares of Immuneering in a research note on Thursday, April 10th. Finally, Oppenheimer cut their price objective on shares of Immuneering from $25.00 to $21.00 and set an “outperform” rating for the company in a research report on Wednesday.

Immuneering Stock Performance

IMRX stock opened at $1.19 on Friday. Immuneering Co. has a 52 week low of $1.00 and a 52 week high of $3.83. The company’s 50-day simple moving average is $1.44 and its 200 day simple moving average is $1.79. The company has a market capitalization of $42.64 million, a PE ratio of -0.60 and a beta of -0.22.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). On average, analysts forecast that Immuneering Co. will post -1.86 EPS for the current year.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.